Heiko Bruhn will be representing GenSearch in Zurich.
Title: 11th Annual European Life Sciences CEO Forum for Partnering & Investing in Biotech & Pharma Industry
Where: Hilton Zurich Airport Hotel | Switzerland
When: 26th-27th February 2018
Back for its 11th Annual edition, this global bio-pharma industry forum addresses through its conference programme the main challenges for 2018 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in the different therapeutic sectors. The Forum also features keynote speeches by KOL, about 60 selected corporate presentations from established (public and private) and emerging biotechs seeking to promote investment and partnering opportunities. There is also a focus on early stage innovation and an elevator session with up 20 presentations by start-ups from BioMed and Digital Health.
On site meetings are facilitated by our online 1-2-1 meeting system, which is available to all participants. We expect up to 350 delegates and 1500+ 1-2-1 meetings to take place on site.
Plenary Sessions will include:
- Global Biopharma Industry Review: Prospects for 2018
- Private Equity and VC: Latest Trends in Fund Raising and Investment
- European Equity Capital Markets: Capital Raising and Investment Opportunities
- Bio-Pharma Partnering: Key Players focusing on DealMaking to Alliance Management
- Early Stage Innovation
- Seed Companies Investor Roundtable
- Rising Stars: Start-Up Showcase
Therapeutic Panels will include:
- Advances in Cell & Gene Therapies
- Neuroscience I – BD&L
- Neuroscience II – Advanced Therapies and Diagnostics
- Oncology I – DealMaking
- Oncology II – Advanced Therapies and Diagnostics
- Platform Technologies and Novel Therapeutics
Interview:
“Going and Being Public: an Interview with Miguel Payró, CFO of GeNeuro SA, Geneva”
by Dr. Søren Bjønness, Director – Swiss Representative, EURONEXT
Keynote Speech:
“The Future of Personalized Healthcare: The Interplay of Diseases, Information and Technologies”
by Miro Venturi, Global Head – Diagnostics Biomarkers, Roche Diagnostics